Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMontreal Heart Institute

About this trial

To demonstrate that a virtual Heart Failure Clinic (HFC) based on patient self-management using Pulmonary Artery Pressure (PAP) monitoring is superior to usual care of HFC, leads to decreased: hospital admissions for heart failure (HF), emergency department consultation and/or unplanned intravenous heart failure therapy and cardiovascular death, compared to a regular HFC, has low device-related complications and is cost-effective, in New York Heart Association (NYHA) class III and II (requiring diuretics) patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female ≥ 18 years old.

Symptomatic HF (NYHA III) with recent heart failure admission in the previous year (12 months). OR

Patient with at least one ER visit or unplanned HF clinic requiring iv diuretics within 12 months will be eligible if they have in addition a N-terminal pro-BNP (NT-proBNP) level > 800pg/ml at screening AND NYHA Class II on diuretics (furosemide ≥ 40mg qd), III or ambulatory IV.

HF with reduced or preserved EF of at least 3 months duration.

Disqualifiers

Recent cardiovascular event: Acute coronary syndrome (STEMI/NSTEMI; a small rise in the troponin level would be expected in this population and is not a contraindication for enrolment); Percutaneous Coronary Intervention (PCI), new cardiac rhythm management (CRM) device (pacemaker, ICD and CRT), CRM system revision, lead extraction or cardiac or other major surgery or transient ischemic attack or stroke within 2 months (3 months of stabilization after CRT or cardiac surgery);

Scheduled cardiac surgery;

History of pulmonary embolism or recurrent deep vein thrombosis;

Persistent NYHA Class IV and ACC/AHA HF Stage D, patients implanted with a ventricular assist device (VAD), or patients listed for cardiac transplantation and likely to be transplanted within 12 months;

Trial design

Design model

Parallel

Treatments tested in this trial

  • CardioMems

    Device

    novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: ControlNo intervention 0 interventions
Group B: CardioMemsActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

first occurrence of any component of the composite event

acute decompensated heart failure requiring emergency department consultation

Time frame
12 months
2

Number of Participants with unplanned intravenous heart failure therapy in an outpatient clinic

unplanned intravenous heart failure therapy in an outpatient clinic

Time frame
12 months
3

Number of Participants with hospital admission for heart failure

hospital admission for heart failure

Time frame
12 months
4

Number of Participants with cardiovascular (CV) death

cardiovascular (CV) death

Time frame
12 months

Secondary outcomes

1

Time to the first occurrence of the individual components of the primary endpoint

Acute decompensated heart failure that requires emergency department consultation and/or unplanned intravenous heart failure therapy in an outpatient clinic

Time frame
12 months
2

Number of Participants with CV death

CV death

Time frame
12 months
3

Change in Quality of life

Quality of life questionnaire

Time frame
12 months
4

Change in functional capacity between baseline and 12-months

NYHA functional class (Kansas city cardiomyopathy questionnaire)

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.